Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 197

1.

Epithelial mesenchymal transition and resistance in endocrine-related cancers.

Culig Z.

Biochim Biophys Acta Mol Cell Res. 2019 Sep;1866(9):1368-1375. doi: 10.1016/j.bbamcr.2019.05.003. Epub 2019 May 18. Review.

PMID:
31108117
2.

CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer.

Frantzi M, Gomez Gomez E, Blanca Pedregosa A, Valero Rosa J, Latosinska A, Culig Z, Merseburger AS, Luque RM, Requena Tapia MJ, Mischak H, Carrasco Valiente J.

Br J Cancer. 2019 Jun;120(12):1120-1128. doi: 10.1038/s41416-019-0472-z. Epub 2019 May 16.

PMID:
31092909
3.

Centrosomal Proteins in Urothelial Tumors: New Pathways in Disease Pathogenesis.

Culig Z.

Am J Pathol. 2019 Jun;189(6):1178-1179. doi: 10.1016/j.ajpath.2019.04.002. Epub 2019 Apr 13.

PMID:
30986383
4.

Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review.

Madersbacher S, Sampson N, Culig Z.

Gerontology. 2019;65(5):458-464. doi: 10.1159/000496289. Epub 2019 Apr 3.

5.

Identification of Potential Novel Candidates for Understanding Racial Differences in Prostate Cancer.

Culig Z.

Eur Urol. 2019 Jan;75(1):16-17. doi: 10.1016/j.eururo.2018.09.038. Epub 2018 Oct 4. No abstract available.

PMID:
30293902
6.

The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models.

Handle F, Puhr M, Schaefer G, Lorito N, Hoefer J, Gruber M, Guggenberger F, Santer FR, Marques RB, van Weerden WM, Claessens F, Erb HHH, Culig Z.

Mol Cancer Ther. 2018 Dec;17(12):2722-2731. doi: 10.1158/1535-7163.MCT-18-0508. Epub 2018 Sep 25.

PMID:
30254184
7.

Systems Oncology: Bridging Pancreatic and Castrate Resistant Prostate Cancer.

Fucic A, Aghajanyan A, Culig Z, Le Novere N.

Pathol Oncol Res. 2018 Sep 16. doi: 10.1007/s12253-018-0467-8. [Epub ahead of print] Review.

PMID:
30220022
8.

The way towards understanding possible multiple functions of AR V7 in prostate cancer.

Culig Z.

BJU Int. 2018 Aug;122(2):169. doi: 10.1111/bju.14406. No abstract available.

9.

Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.

Navone NM, van Weerden WM, Vessella RL, Williams ED, Wang Y, Isaacs JT, Nguyen HM, Culig Z, van der Pluijm G, Rentsch CA, Marques RB, de Ridder CMA, Bubendorf L, Thalmann GN, Brennen WN, Santer FR, Moser PL, Shepherd P, Efstathiou E, Xue H, Lin D, Buijs J, Bosse T, Collins A, Maitland N, Buzza M, Kouspou M, Achtman A, Taylor RA, Risbridger G, Corey E.

Prostate. 2018 Dec;78(16):1262-1282. doi: 10.1002/pros.23701. Epub 2018 Aug 2.

PMID:
30073676
10.

Correction Alternative mechanisms of miR-34a regulation in cancer.

Slabáková E, Culig Z, Remšík J, Souček K.

Cell Death Dis. 2018 Jul 16;9(8):783. doi: 10.1038/s41419-018-0833-1.

11.

Fractionated Radiation of Primary Prostate Basal Cells Results in Downplay of Interferon Stem Cell and Cell Cycle Checkpoint Signatures.

Guggenberger F, van de Werken HJG, Erb HHH, Cappellano G, Trattnig K, Handle F, Peer S, Schäfer G, Jenster G, Culig Z, Skvortsova I, Santer FR.

Eur Urol. 2018 Dec;74(6):847-849. doi: 10.1016/j.eururo.2018.06.002. Epub 2018 Jun 18. No abstract available.

PMID:
29914715
12.

Studies on Steroid Receptor Coactivators in Prostate Cancer.

Culig Z, Santer FR.

Methods Mol Biol. 2018;1786:259-262. doi: 10.1007/978-1-4939-7845-8_15.

PMID:
29786798
13.

Oncolytic activity of the rhabdovirus VSV-GP against prostate cancer.

Urbiola C, Santer FR, Petersson M, van der Pluijm G, Horninger W, Erlmann P, Wollmann G, Kimpel J, Culig Z, von Laer D.

Int J Cancer. 2018 Apr 26. doi: 10.1002/ijc.31556. [Epub ahead of print]

14.

Olaparib is effective in combination with, and as maintenance therapy after, first-line endocrine therapy in prostate cancer cells.

Feiersinger GE, Trattnig K, Leitner PD, Guggenberger F, Oberhuber A, Peer S, Hermann M, Skvortsova I, Vrbkova J, Bouchal J, Culig Z, Santer FR.

Mol Oncol. 2018 Apr;12(4):561-576. doi: 10.1002/1878-0261.12185. Epub 2018 Mar 15.

15.

The "Aging Factor" Eotaxin-1 (CCL11) Is Detectable in Transfusion Blood Products and Increases with the Donor's Age.

Hoefer J, Luger M, Dal-Pont C, Culig Z, Schennach H, Jochberger S.

Front Aging Neurosci. 2017 Dec 1;9:402. doi: 10.3389/fnagi.2017.00402. eCollection 2017.

16.

Interleukin-4 induces a CD44high /CD49bhigh PC3 subpopulation with tumor-initiating characteristics.

Erb HHH, Guggenberger F, Santer FR, Culig Z.

J Cell Biochem. 2018 May;119(5):4103-4112. doi: 10.1002/jcb.26607. Epub 2018 Jan 19.

17.

Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer.

Culig Z.

Curr Mol Biol Rep. 2017;3(4):230-235. doi: 10.1007/s40610-017-0079-1. Epub 2017 Oct 23. Review.

18.

The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy.

Puhr M, Hoefer J, Eigentler A, Ploner C, Handle F, Schaefer G, Kroon J, Leo A, Heidegger I, Eder I, Culig Z, Van der Pluijm G, Klocker H.

Clin Cancer Res. 2018 Feb 15;24(4):927-938. doi: 10.1158/1078-0432.CCR-17-0989. Epub 2017 Nov 20.

19.

Alternative mechanisms of miR-34a regulation in cancer.

Slabáková E, Culig Z, Remšík J, Souček K.

Cell Death Dis. 2017 Oct 12;8(10):e3100. doi: 10.1038/cddis.2017.495. Review. Erratum in: Cell Death Dis. 2018 Jul 16;9(8):783.

20.

Innovative Therapies to Overcome Resistance to Enzalutamide: Perspective on the Use of Darolutamide.

Culig Z.

Eur Urol. 2018 Jan;73(1):9-10. doi: 10.1016/j.eururo.2017.08.024. Epub 2017 Sep 8. No abstract available.

PMID:
28890248
21.

The Molecular Evolution of Castration-resistant Prostate Cancer.

Ceder Y, Bjartell A, Culig Z, Rubin MA, Tomlins S, Visakorpi T.

Eur Urol Focus. 2016 Dec;2(5):506-513. doi: 10.1016/j.euf.2016.11.012. Epub 2016 Dec 9. Review.

PMID:
28723516
22.

Inflammation, Microbiota, and Prostate Cancer.

Puhr M, De Marzo A, Isaacs W, Lucia MS, Sfanos K, Yegnasubramanian S, Culig Z.

Eur Urol Focus. 2016 Oct;2(4):374-382. doi: 10.1016/j.euf.2016.08.010. Epub 2016 Aug 28. Review.

PMID:
28723469
23.

The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling.

Nappo G, Handle F, Santer FR, McNeill RV, Seed RI, Collins AT, Morrone G, Culig Z, Maitland NJ, Erb HHH.

Oncogenesis. 2017 May 29;6(5):e342. doi: 10.1038/oncsis.2017.23.

24.

Interleukin-6 and prostate cancer: Current developments and unsolved questions.

Culig Z, Puhr M.

Mol Cell Endocrinol. 2018 Feb 15;462(Pt A):25-30. doi: 10.1016/j.mce.2017.03.012. Epub 2017 Mar 16. Review.

PMID:
28315704
25.

The role of epithelial-mesenchymal transition drivers ZEB1 and ZEB2 in mediating docetaxel-resistant prostate cancer.

Hanrahan K, O'Neill A, Prencipe M, Bugler J, Murphy L, Fabre A, Puhr M, Culig Z, Murphy K, Watson RW.

Mol Oncol. 2017 Mar;11(3):251-265. doi: 10.1002/1878-0261.12030. Epub 2017 Jan 30.

26.

Predictive and prognostic role of serum neopterin and tryptophan breakdown in prostate cancer.

Pichler R, Fritz J, Heidegger I, Steiner E, Culig Z, Klocker H, Fuchs D.

Cancer Sci. 2017 Apr;108(4):663-670. doi: 10.1111/cas.13171. Epub 2017 Apr 12.

27.

Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer.

Pichler R, Gruenbacher G, Culig Z, Brunner A, Fuchs D, Fritz J, Gander H, Rahm A, Thurnher M.

Cancer Immunol Immunother. 2017 Apr;66(4):427-440. doi: 10.1007/s00262-016-1945-z. Epub 2016 Dec 22.

28.

High-throughput cell-based compound screen identifies pinosylvin methyl ether and tanshinone IIA as inhibitors of castration-resistant prostate cancer.

Ketola K, Viitala M, Kohonen P, Fey V, Culig Z, Kallioniemi O, Iljin K.

J Mol Biochem. 2016 Mar 30;5(1):12-22.

29.

Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer.

Pichler R, Fritz J, Zavadil C, Schäfer G, Culig Z, Brunner A.

Oncotarget. 2016 Jun 28;7(26):39916-39930. doi: 10.18632/oncotarget.9537.

30.

Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide.

Hoefer J, Akbor M, Handle F, Ofer P, Puhr M, Parson W, Culig Z, Klocker H, Heidegger I.

Oncotarget. 2016 Sep 13;7(37):59781-59794. doi: 10.18632/oncotarget.10926.

31.

STAT3 in Prostate Cancer: Whom Should We Treat and When?

Culig Z.

Eur Urol. 2017 Mar;71(3):317-318. doi: 10.1016/j.eururo.2016.06.034. Epub 2016 Jul 9. No abstract available.

PMID:
27402062
32.

JAK-STAT signaling in cancer: From cytokines to non-coding genome.

Pencik J, Pham HT, Schmoellerl J, Javaheri T, Schlederer M, Culig Z, Merkel O, Moriggl R, Grebien F, Kenner L.

Cytokine. 2016 Nov;87:26-36. doi: 10.1016/j.cyto.2016.06.017. Epub 2016 Jun 24. Review.

33.

Breaking a paradigm: IL-6/STAT3 signaling suppresses metastatic prostate cancer upon ARF expression.

Culig Z, Pencik J, Merkel O, Kenner L.

Mol Cell Oncol. 2016 Apr 4;3(2):e1090048. doi: 10.1080/23723556.2015.1090048. eCollection 2016 Mar.

34.

The AR/NCOA1 axis regulates prostate cancer migration by involvement of PRKD1.

Luef B, Handle F, Kharaishvili G, Hager M, Rainer J, Janetschek G, Hruby S, Englberger C, Bouchal J, Santer FR, Culig Z.

Endocr Relat Cancer. 2016 Jun;23(6):495-508. doi: 10.1530/ERC-16-0160. Epub 2016 Jun 2.

35.

SOCS3 Modulates the Response to Enzalutamide and Is Regulated by Androgen Receptor Signaling and CpG Methylation in Prostate Cancer Cells.

Handle F, Erb HH, Luef B, Hoefer J, Dietrich D, Parson W, Kristiansen G, Santer FR, Culig Z.

Mol Cancer Res. 2016 Jun;14(6):574-85. doi: 10.1158/1541-7786.MCR-15-0495. Epub 2016 Apr 6.

36.

New possibilities for urinary molecular diagnostics.

Culig Z.

BJU Int. 2016 Apr;117(4):547-8. doi: 10.1111/bju.13233. No abstract available.

37.

IL-6/STAT3/ARF: the guardians of senescence, cancer progression and metastasis in prostate cancer.

Pencik J, Wiebringhaus R, Susani M, Culig Z, Kenner L.

Swiss Med Wkly. 2015 Dec 21;145:w14215. doi: 10.4414/smw.2015.14215. eCollection 2015. Review.

38.

Erratum: STAT3 regulated ARF expression suppresses prostate cancer metastasis.

Pencik J, Schlederer M, Gruber W, Unger C, Walker SM, Chalaris A, Marié IJ, Hassler MR, Javaheri T, Aksoy O, Blayney JK, Prutsch N, Skucha A, Herac M, Krämer OH, Mazal P, Grebien F, Egger G, Poli V, Mikulits W, Eferl R, Esterbauer H, Kennedy R, Fend F, Scharpf M, Braun M, Perner S, Levy DE, Malcolm T, Turner SD, Haitel A, Susani M, Moazzami A, Rose-John S, Aberger F, Merkel O, Moriggl R, Culig Z, Dolznig H, Kenner L.

Nat Commun. 2015 Oct 26;6:8802. doi: 10.1038/ncomms9802. No abstract available.

PMID:
26499136
39.

Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer.

Kroon J, Puhr M, Buijs JT, van der Horst G, Hemmer DM, Marijt KA, Hwang MS, Masood M, Grimm S, Storm G, Metselaar JM, Meijer OC, Culig Z, van der Pluijm G.

Endocr Relat Cancer. 2016 Jan;23(1):35-45. doi: 10.1530/ERC-15-0343. Epub 2015 Oct 19.

40.

Opposite regulation of MDM2 and MDMX expression in acquisition of mesenchymal phenotype in benign and cancer cells.

Slabáková E, Kharaishvili G, Smějová M, Pernicová Z, Suchánková T, Remšík J, Lerch S, Straková N, Bouchal J, Král M, Culig Z, Kozubík A, Souček K.

Oncotarget. 2015 Nov 3;6(34):36156-71. doi: 10.18632/oncotarget.5392.

41.

Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer.

Perner S, Cronauer MV, Schrader AJ, Klocker H, Culig Z, Baniahmad A.

Oncotarget. 2015 Nov 3;6(34):35542-55. doi: 10.18632/oncotarget.4689. Review.

42.

The Role of Biomarkers and Genetics in the Diagnosis of Prostate Cancer.

Abdollah F, Dalela D, Haffner MC, Culig Z, Schalken J.

Eur Urol Focus. 2015 Sep;1(2):99-108. doi: 10.1016/j.euf.2015.08.001. Epub 2015 Aug 28. Review.

PMID:
28723439
43.

Is Eotaxin-1 a serum and urinary biomarker for prostate cancer detection and recurrence?

Heidegger I, Höfer J, Luger M, Pichler R, Klocker H, Horninger W, Steiner E, Jochberger S, Culig Z.

Prostate. 2015 Dec;75(16):1904-9. doi: 10.1002/pros.23086. Epub 2015 Aug 26.

PMID:
26306920
44.

PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer.

Puhr M, Hoefer J, Eigentler A, Dietrich D, van Leenders G, Uhl B, Hoogland M, Handle F, Schlick B, Neuwirt H, Sailer V, Kristiansen G, Klocker H, Culig Z.

Oncogene. 2016 May 5;35(18):2322-32. doi: 10.1038/onc.2015.292. Epub 2015 Aug 10.

45.

Androgen Receptor Coactivators in Regulation of Growth and Differentiation in Prostate Cancer.

Culig Z.

J Cell Physiol. 2016 Feb;231(2):270-4. doi: 10.1002/jcp.25099. Review.

PMID:
26201947
46.

STAT3 regulated ARF expression suppresses prostate cancer metastasis.

Pencik J, Schlederer M, Gruber W, Unger C, Walker SM, Chalaris A, Marié IJ, Hassler MR, Javaheri T, Aksoy O, Blayney JK, Prutsch N, Skucha A, Herac M, Krämer OH, Mazal P, Grebien F, Egger G, Poli V, Mikulits W, Eferl R, Esterbauer H, Kennedy R, Fend F, Scharpf M, Braun M, Perner S, Levy DE, Malcolm T, Turner SD, Haitel A, Susani M, Moazzami A, Rose-John S, Aberger F, Merkel O, Moriggl R, Culig Z, Dolznig H, Kenner L.

Nat Commun. 2015 Jul 22;6:7736. doi: 10.1038/ncomms8736. Erratum in: Nat Commun. 2015;6:8802.

47.

ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat.

Meidhof S, Brabletz S, Lehmann W, Preca BT, Mock K, Ruh M, Schüler J, Berthold M, Weber A, Burk U, Lübbert M, Puhr M, Culig Z, Wellner U, Keck T, Bronsert P, Küsters S, Hopt UT, Stemmler MP, Brabletz T.

EMBO Mol Med. 2015 Jun;7(6):831-47. doi: 10.15252/emmm.201404396.

48.

Low prevalence of HPV detection and genotyping in non-muscle invasive bladder cancer using single-step PCR followed by reverse line blot.

Pichler R, Borena W, Schäfer G, Manzl C, Culig Z, List S, Neururer S, Von Laer D, Heidegger I, Klocker H, Horninger W, Steiner H, Brunner A.

World J Urol. 2015 Dec;33(12):2145-51. doi: 10.1007/s00345-015-1539-y. Epub 2015 Mar 19.

PMID:
25786709
49.

Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy.

Santer FR, Erb HH, Oh SJ, Handle F, Feiersinger GE, Luef B, Bu H, Schäfer G, Ploner C, Egger M, Rane JK, Maitland NJ, Klocker H, Eder IE, Culig Z.

Oncotarget. 2015 Mar 20;6(8):6105-22.

50.

Akacid medical formulation induces apoptosis in myeloid and lymphatic leukemic cell lines in vitro and in vivo.

Neuwirt H, Wabnig E, Feistritzer C, Eder IE, Salvador C, Puhr M, Culig Z, Massoner P, Tiefenthaler M, Steurer M, Konwalinka G.

PLoS One. 2015 Feb 13;10(2):e0117806. doi: 10.1371/journal.pone.0117806. eCollection 2015.

Supplemental Content

Support Center